MedPath

A Study to Assess the effect of Subcutaneous APL-2 in Healthy Adult Subjects

Phase 1
Completed
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Blood - Haematological diseases
Registration Number
ACTRN12614000725662
Lead Sponsor
Clinical Network Services (CNS) Pty Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
31
Inclusion Criteria

Healthy adult male or female subject; body mass index (BMI) between 18.5 and 32.0 kg/m2; weight between 60.0 kg and 80.0 kg.

Exclusion Criteria

* Subject is mentally or legally incapacitated or has significant emotional problems; or has a history of: clinically significant medical or psychiatric condition or disease, any illness that might confound the results of the study or pose a risk to the subject by their participation in the study, alcoholism or drug abuse, and/or hypersensitivity or idiosyncratic reaction to compounds related to APL-2 or particular antibiotics.
*Infection within the last 4 weeks
*Female subjects who are pregnant or lactating.
*Use of any prescription and non-prescription medications, herbal remedies, or vitamin supplements within the last 14 days, or use of some particular drugs such as St. John’s Wort within the last 28 days, up until the end of the study (paracetamol may be permitted)
*Blood donation or significant blood loss within the past 56 days or plasma donation within the last 7 days.
*Participation in another clinical trial within the past 28 days
*Significant surgery within the past 90 days
*Presence of any scars or tattoos on the abdomen which may obscure the injection site

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath